The Wroclaw-based company has raised PLN 5.1 million. This will accelerate the development of remote endoscopy

Wroclaw-based BioCam, a deep-tech company, has been developing remote capsule endoscopy technology for the digestive system for several years. It has just secured PLN 5.1 million from business angels to develop its innovations. The company's investors include Level2 Ventures, Smartlink Partners from the JRH group, LT Capital from the Movens Capital group, and Dawid Urban together with a group of private investors.

The closing of the next round marks the entry into an even higher level of technological readiness and operational efficiency. After several years of intensive research and development, we are smoothly moving on to the stage of medium-series production and commercialization. BioCam has become a company ready to scale not only in Poland but also in foreign markets.

Maciej Wysocki, President of BioCam

The funds raised will allow the company to continue its intensive development. It will be able to move from intensive research and development to the launch of medium-scale production and the preparation of the first commercial implementations in veterinary medicine, as well as the continuation of work on a new generation of endoscopic capsules.

An opportunity to introduce endoscopic capsules for humans

BioCam is currently developing devices capable of imaging not only with white light, but also with a narrow NBI spectrum, which will significantly improve diagnostic quality. The new version of the capsule achieves up to 30 hours of battery life (previously 10-12 hours) and records 150,000 to 300,000 images during a single examination, which is several times more than the prototypes presented in previous years.

Currently, the company's activities are focused on exploiting the potential of the capsule's veterinary applications. However, significant technological progress is paving the way for BioCam to obtain medical device certification and introduce the device to the human medicine market as early as 2027.

Clinical trials on patients coming soon

In recent months, the company has also obtained two key grants. The first, from EU Funds for Lower Silesia, supports the development of NBI modules, increasing the frequency of recorded images, and preparing and conducting clinical trials on 128 patients, which is a fundamental part of the certification process in Europe. The second grant, “Way to North America” from PARP, worth PLN 340,000, enables the company to begin work on entering the US market, including the establishment of a local special purpose vehicle.

Today, we have the funds, partnerships, a ready roadmap for commercialization, and a real opportunity to conduct clinical trials in the very near future that will unlock access to the human medicine market. After five years of intensive development work, we are now one step away from scaling up production and achieving our first significant sales.

Maciej Wysocki

Profitability getting closer

The company has already signed distribution agreements for the Italian and Lithuanian veterinary markets. Talks on exclusivity on the Polish market are also being finalized. The company also has seven representation agreements covering, among others, Germany, Portugal, Iceland, India, North Africa, Saudi Arabia, and the GULF region. Work is also underway to select partners in North America, where Wrocław's technology has the best chance of finding commercial application.

According to current forecasts, BioCam expects to generate revenues from the veterinary segment of at least PLN 2-3 million in 2026. The first sales invoices should be issued later this year, while the full commercialization launch is planned for the turn of January and February 2026. The company expects to achieve profitability at the end of 2027, subject to further technological development and continued R&D spending, which has so far accounted for 90% of its operating expenses.

Plans to go public

BioCam still plans to enter NewConnect next year, but the final decision will depend on the market situation.

From the outset, plans to go public were linked to the intention to gain access to an effective source of raising more capital in a very difficult period for deep tech companies. In the current market environment, we need to have several parallel paths that will allow us to finance further technology development. Therefore, we do not rule out remaining on the VC path with a greater emphasis on foreign investors.

Maciej Wysocki

How does BioCam technology work in practice?

At first glance, the capsule swallowed by the patient resembles a vitamin C tablet. Within an average of about 12 hours, it passes through the entire digestive system, monitoring it with high-resolution cameras and creating a catalog of over 150,000 images, which are then verified by an advanced image analysis system. AI algorithms using machine learning select images, which are then sent to a mobile application and telemedicine platform available to the doctor. The software automatically detects pathological changes, which can be viewed in a doctor's office in as little as 20-30 minutes. This type of examination reduces the time spent by medical professionals several times over.